C Ray Therapeutics Strengthens Radiopharma Platform With AAALAC Accreditation and Focus on Localized Alpha Therapies

C Ray Therapeutics, a China-based radiopharmaceutical CRDMO, featured prominently this week as it sharpened its strategic focus on localized alpha therapies for peritoneal metastases and expanded its global credibility in preclinical development. The company highlighted the limitations of systemic chemotherapy and conventional radioligand approaches in treating micrometastases in ovarian and gastrointestinal cancers.

Through recent communications, C Ray emphasized a shift from drug potency to delivery geometry, spotlighting Ra-224–based localized alpha therapy that targets surface-level micrometastases while sparing critical organs. The firm is co-organizing the International RDC Sub-Forum at the XDC Conference 2026 in Chengdu, where Oncoinvent CEO Oystein Soug is expected to lead a session on receptor-independent regional alpha therapies.

Management indicated that scalable, GMP-compliant manufacturing and a diversified radiopharmaceutical toolkit will be essential for advancing localized alpha platforms, implying an opportunity for C Ray to position itself as a specialized CDMO partner. These themes point to a niche yet high-need oncology segment where successful therapies could command premium pricing, though the communications stopped short of detailing specific pipeline assets or commercial timelines.

Operationally, C Ray reported securing AAALAC International Full Accreditation for its 28,000-square-meter Chengdu animal care facility, which integrates accredited preclinical services with cGMP manufacturing under China’s Class A Radiation Safety License. The site can handle more than 30 radioisotopes, including Actinium-225, and has supported over 70 projects, 16 investigator-initiated trials, and multiple programs now in Phase III.

The company underscored that AAALAC accreditation is intended to support Western-grade regulatory submissions and differentiate it for global partners focused on ethics and data integrity in China-based studies. C Ray claims its framework can compress first-in-human timelines to roughly six to nine months, with five programs supported through IND or IND-enabling stages and three in clinical supply, suggesting growing depth in its service portfolio.

At the TRP Summit 2026 in Boston, C Ray contributed to industry discussions on Phase Zero and first-in-human radiopharmaceutical trials, including theragnostic design trade-offs and the pairing of therapeutic agents with companion diagnostics. The firm highlighted nuanced U.S. FDA expectations for overseas investigator-initiated trial data, noting that high-quality, well-documented safety data from China can sometimes avoid duplicative trials and save about 12 months in development.

Taken together, the week’s developments indicate C Ray is reinforcing both its scientific thought leadership in localized alpha therapy and its operational infrastructure in global radiopharma services. While no new financial metrics were disclosed beyond previously raised capital, the AAALAC accreditation, manufacturing focus, and regulatory strategy appear to strengthen the company’s positioning for future partnerships and long-term competitiveness in the radiopharmaceutical value chain.